Imagine a microscopic-scale missile system designed to hunt down and destroy rogue cancer cells one by one, while leaving healthy tissue completely untouched. That is the revolutionary promise of targeted alpha therapy, a cutting-edge field of medicine using specialized radioactive particles. By attaching these powerful alpha emitters to targeting molecules, doctors can deliver localized radiation […]
Archive for July, 2026
A microscopic-scale missile system designed to hunt down and destroy rogue cancer cells
Posted by Michael A. S. Guth on July 30th, 2026
Posted in Pharma and Medical Device, Regulatory Medical Writing 
Comments Off on A microscopic-scale missile system designed to hunt down and destroy rogue cancer cellsSuccessful integration of Lead-212-targeted alpha therapy into routine clinical practice
Posted by Michael A. S. Guth on July 30th, 2026
Targeted alpha therapy (TAT) represents a transformative shift in precision oncology, offering high linear energy transfer over extremely short cellular paths to eradicate treatment-resistant malignancies. However, translating these powerful radioisotopes from the bench to the bedside introduces complex operational and toxicological bottlenecks. Chief among these is the management of transient daughter radionuclides like Lead-212 and […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on Successful integration of Lead-212-targeted alpha therapy into routine clinical practiceTargeting TDP-43 in ALS: Regulatory Hurdles, Trial Design Deficiencies, and the Causal Evidence Gap for CTx1000
Posted by Michael A. S. Guth on July 29th, 2026
๐๐ฆ๐ฒ๐จ๐ญ๐ซ๐จ๐ฉ๐ก๐ข๐ ๐ฅ๐๐ญ๐๐ซ๐๐ฅ ๐ฌ๐๐ฅ๐๐ซ๐จ๐ฌ๐ข๐ฌ (๐๐๐) ๐ข๐ฌ ๐ ๐๐๐ญ๐๐ฅ ๐ง๐๐ฎ๐ซ๐จ๐๐๐ ๐๐ง๐๐ซ๐๐ญ๐ข๐ฏ๐ ๐๐ข๐ฌ๐๐๐ฌ๐. ๐๐๐๐ข๐๐ง ๐ฌ๐ฎ๐ซ๐ฏ๐ข๐ฏ๐๐ฅ ๐๐ซ๐จ๐ฆ ๐ฌ๐ฒ๐ฆ๐ฉ๐ญ๐จ๐ฆ ๐จ๐ง๐ฌ๐๐ญ ๐ข๐ฌ ๐๐ ๐ญ๐จ ๐๐ ๐ฆ๐จ๐ง๐ญ๐ก๐ฌ, ๐๐ง๐ ๐๐จ๐ซ ๐ฆ๐จ๐ฌ๐ญ ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ, ๐ง๐จ ๐๐ฏ๐๐ข๐ฅ๐๐๐ฅ๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ ๐ฆ๐๐๐ง๐ข๐ง๐ ๐๐ฎ๐ฅ๐ฅ๐ฒ ๐ฌ๐ฅ๐จ๐ฐ๐ฌ ๐ญ๐ก๐๐ญ ๐๐๐๐ฅ๐ข๐ง๐. Since riluzole’s 1995 approval โ which extended median survival by only weeks โ more than 60 compounds have entered clinical trials for ALS, and nearly […]
Posted in Aging Adults, Neuroplasticity, Regulatory Medical Writing Comments Off on Targeting TDP-43 in ALS: Regulatory Hurdles, Trial Design Deficiencies, and the Causal Evidence Gap for CTx1000“๐๐ก๐ ๐ช๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง ๐ข๐ฌ ๐ง๐จ๐ญ ๐ฐ๐ก๐๐ญ ๐ฒ๐จ๐ฎ ๐ฅ๐จ๐จ๐ค ๐๐ญ, ๐๐ฎ๐ญ ๐ฐ๐ก๐๐ญ ๐ฒ๐จ๐ฎ ๐ฌ๐๐.” โ ๐๐๐ง๐ซ๐ฒ ๐๐๐ฏ๐ข๐ ๐๐ก๐จ๐ซ๐๐๐ฎ
Posted by Michael A. S. Guth on July 28th, 2026
“๐๐ก๐ ๐ช๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง ๐ข๐ฌ ๐ง๐จ๐ญ ๐ฐ๐ก๐๐ญ ๐ฒ๐จ๐ฎ ๐ฅ๐จ๐จ๐ค ๐๐ญ, ๐๐ฎ๐ญ ๐ฐ๐ก๐๐ญ ๐ฒ๐จ๐ฎ ๐ฌ๐๐.” โ ๐๐๐ง๐ซ๐ฒ ๐๐๐ฏ๐ข๐ ๐๐ก๐จ๐ซ๐๐๐ฎ For decades, Alzheimer’s research has looked at the same data: amyloid plaques, tau tangles, neuroinflammation. But what if we have been seeing it wrong? Two underappreciated forcesโchronic stress and an oral bacterium called P. gingivalisโmay be converging on the […]
Posted in Aging Adults, Neuroplasticity, Pharma and Medical Device Comments Off on “๐๐ก๐ ๐ช๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง ๐ข๐ฌ ๐ง๐จ๐ญ ๐ฐ๐ก๐๐ญ ๐ฒ๐จ๐ฎ ๐ฅ๐จ๐จ๐ค ๐๐ญ, ๐๐ฎ๐ญ ๐ฐ๐ก๐๐ญ ๐ฒ๐จ๐ฎ ๐ฌ๐๐.” โ ๐๐๐ง๐ซ๐ฒ ๐๐๐ฏ๐ข๐ ๐๐ก๐จ๐ซ๐๐๐ฎ๐๐ก๐ ๐ข๐ง๐ญ๐ซ๐๐๐๐ฅ๐ฅ๐ฎ๐ฅ๐๐ซ ๐ฅ๐จ๐๐ค๐๐จ๐ฑ: ๐ก๐ฒ๐ฉ๐๐ซ๐ฉ๐ก๐จ๐ฌ๐ฉ๐ก๐จ๐ซ๐ฒ๐ฅ๐๐ญ๐๐ ๐ญ๐๐ฎ: ๐จ๐ง๐ ๐๐ฌ๐ฉ๐๐๐ญ ๐จ๐ ๐ญ๐ก๐ ๐๐ฎ๐๐ฅ ๐๐๐ช๐ฎ๐๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง ๐๐ฒ๐ฉ๐จ๐ญ๐ก๐๐ฌ๐ข๐ฌ ๐๐ฒ ๐๐ข๐๐ก๐๐๐ฅ ๐. ๐. ๐๐ฎ๐ญ๐ก
Posted by Michael A. S. Guth on July 27th, 2026
While Aฮฒ patrols the extracellular space, the microtubule-associated protein tau functions within neurons. In its normal state, tau stabilizes micro-tubules, which are crucial for axonal transport and structural integrity. Its pathological transformation into hyperphosphorylated, aggregated NFTs is another diagnostic hallmark of AD and strongly correlates with cognitive decline (Jellinger, 2020). The DSH suggests viewing pathological […]
Posted in Aging Adults, Neuroplasticity, Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐๐ก๐ ๐ข๐ง๐ญ๐ซ๐๐๐๐ฅ๐ฅ๐ฎ๐ฅ๐๐ซ ๐ฅ๐จ๐๐ค๐๐จ๐ฑ: ๐ก๐ฒ๐ฉ๐๐ซ๐ฉ๐ก๐จ๐ฌ๐ฉ๐ก๐จ๐ซ๐ฒ๐ฅ๐๐ญ๐๐ ๐ญ๐๐ฎ: ๐จ๐ง๐ ๐๐ฌ๐ฉ๐๐๐ญ ๐จ๐ ๐ญ๐ก๐ ๐๐ฎ๐๐ฅ ๐๐๐ช๐ฎ๐๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง ๐๐ฒ๐ฉ๐จ๐ญ๐ก๐๐ฌ๐ข๐ฌ ๐๐ฒ ๐๐ข๐๐ก๐๐๐ฅ ๐. ๐. ๐๐ฎ๐ญ๐กHas the definition of “positive neuroplasticity”ย and “negative neuroplasticity” evolved over time?
Posted by Michael A. S. Guth on July 23rd, 2026
Has the definition of “positive neuroplasticity”ย and “negative neuroplasticity” evolved over time? This publication,ย Vance DE, Roberson AJ, McGuinness TM, Fazeli PL. Howย neuroplasticity and cognitive reserve protect cognitive functioning. Jย Psychosoc Nurs Ment Health Serv. 2010 Apr;48(4):23-30. doi:ย 10.3928/02793695-20100302-01. PMID: 20349891,ย defined โPositive neuroplasticity refers to he physiologicalย ability of the brain to form and strengthen dendritic connections, produceย beneficial morphological changes, […]
Posted in Neuroplasticity, Pharma and Medical Device, Regulatory Medical Writing Comments Off on Has the definition of “positive neuroplasticity”ย and “negative neuroplasticity” evolved over time?๐๐ฎ๐๐ฅ ๐๐๐ช๐ฎ๐๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง ๐๐ฒ๐ฉ๐จ๐ญ๐ก๐๐ฌ๐ข๐ฌ ๐๐จ๐ซ ๐๐ฅ๐ณ๐ก๐๐ข๐ฆ๐๐ซ’๐ฌ ๐๐ข๐ฌ๐๐๐ฌ๐: ๐๐ก๐ ๐๐ฑ๐ญ๐ซ๐๐๐๐ฅ๐ฅ๐ฎ๐ฅ๐๐ซ ๐ฌ๐๐ซ๐๐จ๐ฉ๐ก๐๐ ๐ฎ๐ฌ: ๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐-ฮฒย
Posted by Michael A. S. Guth on July 20th, 2026
๐๐ง ๐จ๐ฎ๐ซ ๐๐ฎ๐๐ฅ ๐๐๐ช๐ฎ๐๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง ๐๐ฒ๐ฉ๐จ๐ญ๐ก๐๐ฌ๐ข๐ฌ ๐๐จ๐ซ ๐๐ฅ๐ณ๐ก๐๐ข๐ฆ๐๐ซ’๐ฌ ๐๐ข๐ฌ๐๐๐ฌ๐: ๐๐ก๐ ๐๐ฑ๐ญ๐ซ๐๐๐๐ฅ๐ฅ๐ฎ๐ฅ๐๐ซ ๐ฌ๐๐ซ๐๐จ๐ฉ๐ก๐๐ ๐ฎ๐ฌ: ๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐-ฮฒย We suggest reframing the Aฮฒ plaque not as a pathogenic endpoint but as an extracellular sarcophagusโa first-responder mechanism that sequesters insoluble or toxic material in the interstitial space. This view is supported by substantial evidence challenging Aฮฒ’s role as merely metabolic waste. From […]
Posted in Aging Adults, Neuroplasticity, Pharma and Medical Device Comments Off on ๐๐ฎ๐๐ฅ ๐๐๐ช๐ฎ๐๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง ๐๐ฒ๐ฉ๐จ๐ญ๐ก๐๐ฌ๐ข๐ฌ ๐๐จ๐ซ ๐๐ฅ๐ณ๐ก๐๐ข๐ฆ๐๐ซ’๐ฌ ๐๐ข๐ฌ๐๐๐ฌ๐: ๐๐ก๐ ๐๐ฑ๐ญ๐ซ๐๐๐๐ฅ๐ฅ๐ฎ๐ฅ๐๐ซ ๐ฌ๐๐ซ๐๐จ๐ฉ๐ก๐๐ ๐ฎ๐ฌ: ๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐-ฮฒย Do the Biogen Diranersen Phase 2 (Celia study) results provide counter-evidence to my Dual Sequestration Hypothesis?
Posted by Michael A. S. Guth on July 14th, 2026
DSH vs. Biogen Diranersen Phase 2 (Celia study) โ Compatibility Assessment Bottom line: The Celia results do not constitute counter-evidence to DSH. They’re compatible with its core claim about therapeutic ceilings, but nothing in the trial tests DSH’s actual falsifiable content (nanoplastic nucleation, glymphatic obstruction, NLRP3/pyroptosis, NP-tangle colocalization). Log this as consistent-with, not confirmatory-of. 1. […]
Posted in Neuroplasticity, Pharma and Medical Device, Regulatory Medical Writing Comments Off on Do the Biogen Diranersen Phase 2 (Celia study) results provide counter-evidence to my Dual Sequestration Hypothesis?Resistance Training and Neuroplasticity
Posted by Michael A. S. Guth on July 14th, 2026
Recent research (Vints et al., 2024, GeroScience) offers critical insights into the biological underpinnings of how resistance training influences the aging brain. By utilizing a randomized controlled trial design, the study examined 70 older adults (aged 60โ85) stratified by MCI risk via MoCA scores, shedding light on the structural and neurochemical shifts induced by a […]
๐๐ก๐ ๐ก๐ข๐ฌ๐ญ๐จ๐ซ๐ข๐๐๐ฅ ๐ ๐ซ๐๐๐ข๐๐ง๐ญ ๐จ๐ ๐๐ฅ๐ณ๐ก๐๐ข๐ฆ๐๐ซ’๐ฌ ๐ญ๐ซ๐ข๐ ๐ ๐๐ซ๐ฌ
Posted by Michael A. S. Guth on July 13th, 2026
๐๐ก๐ ๐ก๐ข๐ฌ๐ญ๐จ๐ซ๐ข๐๐๐ฅ ๐ ๐ซ๐๐๐ข๐๐ง๐ญ ๐จ๐ ๐๐ฅ๐ณ๐ก๐๐ข๐ฆ๐๐ซ’๐ฌ ๐ญ๐ซ๐ข๐ ๐ ๐๐ซ๐ฌย from industrial contaminants to theย Plasticene A complete understanding of the Dual Sequestration Hypothesisย requires situating the Plasticeneย trigger within a broader historical timeline of escalating environmental neural incursion. AD was not absent before the modern eraโhistorical cases existโbut its incidence has risen dramatically over the past century in a pattern that cannot […]
Posted in Aging Adults, Neuroplasticity, Regulatory Medical Writing Comments Off on ๐๐ก๐ ๐ก๐ข๐ฌ๐ญ๐จ๐ซ๐ข๐๐๐ฅ ๐ ๐ซ๐๐๐ข๐๐ง๐ญ ๐จ๐ ๐๐ฅ๐ณ๐ก๐๐ข๐ฆ๐๐ซ’๐ฌ ๐ญ๐ซ๐ข๐ ๐ ๐๐ซ๐ฌ